|
1
|
Li C and Hong W: Research status and
funding trends of lung cancer biomarkers. J Thorac Dis. 5:698–705.
2013.PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ettinger DS, Wood DE, Akerley W, Bazhenova
LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA,
Demmy TL, et al: Non-small cell lung cancer, version 1.2015. J Natl
Compr Canc Netw. 12:1738–1761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shanker M, Willcutts D, Roth JA and Ramesh
R: Drug resistance in lung cancer. Lung Cancer (Auckl). 1:23–36.
2010.PubMed/NCBI
|
|
5
|
Efferth T, Li PC, Konkimalla VS and Kaina
B: From traditional Chinese medicine to rational cancer therapy.
Trends Mol Med. 13:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu J, Xu J and Shi Q: Effect of ethanol
extract of HPRS, a Traditional Chinese Medicine formula, on HCT116
cell line. J Tradit Chin Med. 36:760–767. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han R: Highlight on the studies of
anticancer drugs derived from plants in China. Stem Cells.
12:53–63. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiao L, Wang Y, Xu L and You M: Lung
cancer prevention and therapy using the JinFuKang herbal mixture.
Curr Pharmacol Rep. 1:346–353. 2015. View Article : Google Scholar
|
|
9
|
Sun JL and Liu JX: Effect of ‘Jinfukang
Oral Solution’ on expression of apoptosis related genes of human
lung adenocarcinoma cells transplanted in nude mice. Shanghai J
Tradit Chin Med. 10:2007.
|
|
10
|
Liu JX, Shi ZM, Li HG, Xu ZY, Zhu YW, Zhao
LH, Gao H, Liu LS, Zhu HR and Zhang H: Clinical observation on 271
cases of non-small cell lung cancer treated with Yifei Kangliu Yin.
Chin J Integr Tradit West Med. 7:247–250. 2001.
|
|
11
|
Xue R, Fang Z, Zhang M, Yi Z, Wen C and
Shi T: TCMID: Traditional Chinese medicine integrative database for
herb molecular mechanism analysis. Nucleic Acids Res. 41(Database
issue): D1089–D1095. 2013.PubMed/NCBI
|
|
12
|
Bonham M, Arnold H, Montgomery B and
Nelson PS: Molecular effects of the herbal compound PC-SPES:
Identification of activity pathways in prostate carcinoma. Cancer
Res. 62:3920–3924. 2002.PubMed/NCBI
|
|
13
|
Lu J, Chen J, Xu N, Wu J, Kang Y, Shen T,
Kong H, Ma C, Cheng M, Shao Z, et al: : Activation of AIFM2
enhances apoptosis of human lung cancer cells undergoing
toxicological stress. Toxicol Lett. 258:227–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pickrell JK, Marioni JC, Pai AA, Degner
JF, Engelhardt BE, Nkadori E, Veyrieras JB, Stephens M, Gilad Y and
Pritchard JK: Understanding mechanisms underlying human gene
expression variation with RNA sequencing. Nature. 464:768–772.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Gerstein M and Snyder M: RNA-Seq:
A revolutionary tool for transcriptomics. Nat Rev Genet. 10:57–63.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Zhang X, Shen T, Ma C, Wu J, Kong H,
Tian J, Shao Z, Zhao X and Xu L: Epigenetic profiling of H3K4Me3
reveals herbal medicine Jinfukang-induced epigenetic alteration is
involved in anti-lung cancer activity. Evid Based Complement
Alternat Med. 2016:132016. View Article : Google Scholar
|
|
17
|
Qi Y, Zhang X, Kang Y, Wu J, Chen J, Li H,
Guo Y, Liu B, Shao Z and Zhao X: Genome-wide transcriptional
profiling analysis reveals annexin A6 as a novel EZH2 target gene
involving gastric cellular proliferation. Mol Biosyst.
11:1980–1986. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Trapnell C, Roberts A, Goff L, Pertea G,
Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L:
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks. Nat Protoc. 7:562–578. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hesketh T and Zhu WX: Health in China.
Traditional Chinese medicine: One country, two systems. BMJ.
315:115–117. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cassileth BR, Rizvi N, Deng G, Yeung KS,
Vickers A, Guillen S, Woo D, Coleton M and Kris MG: Safety and
pharmacokinetic trial of docetaxel plus an Astragalus-based herbal
formula for non-small cell lung cancer patients. Cancer Chemother
Pharmacol. 65:67–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nigg EA: Cyclin-dependent protein kinases:
Key regulators of the eukaryotic cell cycle. Bioessays. 17:471–480.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chohan TA, Qian H, Pan Y and Chen JZ:
Cyclin-dependent kinase-2 as a target for cancer therapy: Progress
in the development of CDK2 inhibitors as anti-cancer agents. Curr
Med Chem. 22:237–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Volm M, Koomägi R, Mattern J and Stammler
G: Cyclin A is associated with an unfavourable outcome in patients
with non-small-cell lung carcinomas. Br J Cancer. 75:1774–1778.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu
D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage
non-small cell lung cancer and its clinical implication. Cancer
Res. 60:4000–4004. 2000.PubMed/NCBI
|
|
29
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oh SB, Hwang CJ, Song SY, Jung YY, Yun HM,
Sok CH, Sung HC, Yi JM, Park DH, Ham YW, et al: Anti-cancer effect
of tectochrysin in NSCLC cells through overexpression of death
receptor and inactivation of STAT3. Cancer Lett. 353:95–103. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kobayashi S, Kajino S, Takahashi N,
Kanazawa S, Imai K, Hibi Y, Ohara H, Itoh M and Okamoto T: 53BP2
induces apoptosis through the mitochondrial death pathway. Genes
Cells. 10:253–260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fei P, Wang W, Kim Sh, Wang S, Burns TF,
Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ and El-Deiry
WS: Bnip3L is induced by p53 under hypoxia, and its knockdown
promotes tumor growth. Cancer Cell. 6:597–609. 2004. View Article : Google Scholar : PubMed/NCBI
|
